





2024

ESG



C2


ESG



2024 1 1 12 31

2






2024



ESG




ESG



ESG

[illegible]


	• • • • •	• • •
	• • • • •	• • • • •
	• • • • •	• • • • •
	• • •	• •
	• • •	• • • •
	• • •	• • • •
	• • •	• • • • •





01





			✓	✓	✓
		✓		✓	
		✓	✓	✓	✓
		✓	✓		
					✓
				✓	
			✓	✓	
			✓		


2024

8 1 4


8

1

4



2024




2024 16



2024

27



近期医药执法典型案例一览



《深化医药卫生体制改革2024年重点工作任务》解读




100%

2024

0

100%



2024 6



2024

100%

2024

0





-
-
-
-

-
-
-

-

- 2024

2

2,309

2,271

38



2024



ESG

	2024105
	- ISO 14001 1,800202418
	- EHS

02






15.23

150

974

417





I II III



50	150	58	2024 25
	2021		
	2024	3	
	3	12	
2024			
2024			



20241

frst-in-class

FIC


FIC

100%



	417	1,557	26
2024	380	70	12
2024	45	73	12





14 100 8


	3CL	3CL
	2015	
	/	G1
	PD- L 1	
	EGFR	
		FDA



®



2024	8	®	FDA		
		2024	12	H20240041	AIS
		®			
		®		AIS	





45

45

34

34



®



2024 11 — 466 92% 2022 7

First-in-Class

FDA



®

2024 11 EGFR — 61%

2024

2024

®

®



®



2024

O2O

O2O

®



2024

6

03




42

23

100%

100%





2024

ISO 9001: 2015

MNC

2024

42

GMP

50

GMP

FDA

FDA

2024

42

50



RMP



-
-



-
-



-
-



-

67

SOP

SOP

100%



100%



100%



100%



2024



3

2

GSP


5

98.25%





k



2024



100%

287

12,606

23

287

100%

12,606

23



PV

3,818

2 17

3,818
100%

2 17

2024



100%






2024

4




04





is used for the cell seed expansion


BR and 500L BR level and cell culture




7



2024



2024



2024



2024 11



/

2024

1,095 495

	2024	4	
		30%	7%
			2024



2024

43

3,000 20,000



— 2024

6,763.21

2024

CFR Conversation, Feedback, Recognition
CFR





2024
GSP

8

2 60



- FMDP First-Line Management Development Plan

42



●

6

75



●

2024 1

53




E	2024	e				
	10					
	188	24,498				
	44,405					
	16	9				
		43				
	2024					
		10				
	11	10				
	4	120				
	94/100					



2024

2024



100%

100%

100%

100%

100%

η Æ

2024


2024

204

48.55



	• 2024 20
	• 2024 6,543 6,428 5,400 4.51
	• CEO
	• /



•

•

•

 $\bar{\alpha}$

æ ʏ

2024 9

٢

$$y \propto \sigma :$$

£



HR





k

! ! !

k




EHS

2024

2024



2024





301²

2024	2023	2022
0	0	0

2024	
100%	
EHS 100%	
100%	

2024

2024




-
-
-

- 100%
-
-

-
-

2024







2024

2024

05








CODSS

	2024	2023	2022
	464,553.74	436,299.00	418,149.48
	/0.70	0.66	0.66
COD	19.98	20.43	14.60
SS	7.25	8.04	6.66
	0.77	1.81	0.87

2024



2024	9
------	---

	2024	2023	2022
	2,972.19	2,152.18	1,574.04
/	4.48 ⁸	3.26	2.49
	1,885.34	1,896.69	1,826.24
/	2.84	2.87	2.89

2024



4,500




2024	6		
11	2.1		
	15	4,200	

⁸ 2024



	2024	2023	2022
	995,024.42	1,178,901.14	1,109,243.84
/	1.50	1.78	1.76

4





	2024	6.68kg/
30		2.71.9



2024EHS




2024





06





2024 7

200

27.4




2024 6

10



2024 19



200



146

2024

175,200



59,225.62



19,100 ml

2024 73



2024



ESG

	A1	a	P71-72
		b	
		A1.1	P71-72
		A1.3	P73
		A1.4	P73
		A1.5	P70-72
		A1.6	P70 P72
			P73
	A2	A2.1	P79
		A2.2	P74
		A2.3	P70 P75
		A2.4	P73
		A2.5	/
			P70
	A3	A3.1	P70 P73

	B1		P50-55
		a	
		b	
		B1.1	P51
	B2	B1.2	P51
		a	P64-66
		b	
	B3	B2.1	P66
		B2.2	P66
		B2.3	P66-67
			P55
	B4	B3.1	P59
		B3.2	P59
			P50
		a	
		b	
		B4.1	P50
		B4.2	P50



	B5		P21-23
		B5.1	P22
		B5.2	P21-22
		B5.3	P23
		B5.4	P23
	B6		P34-35
		a	P38-45
		b	
		B6.1	P41
		B6.2	P46
		B6.3	P29
		B6.4	P38-41
		B6.5	P46-47
	B7		P19-20
		a	
		b	
		B7.1	P20
		B7.2	P19-20
	B8		P82-83
		B8.1	P83
		B8.2	P83

			P76
			P77-78
			P76-77
			P76
			/
			/
			/
			P76
			P78
			P77
			P77
			P78
			/
			/
			/
			/
			/
			/
			/
			/
			/
			/



AAALAC
GMP
2009 11 27
2015 11 30
EHS
1993 4 28
1995 3 28
2017 7 10
1999 6 30
2000 7 20
1998 9 10
2022 3 11

	ESG	2024	ESG	ESG
1.				
☐	☐	☐	☐	☐
☐	☐	/NGO	☐	
2.				
☐	☐	☐	☐	
3.				
☐	☐	☐	☐	
4.				
☐	☐	☐	☐	
5.				
☐	☐	☐	☐	
6.				
☐	☐	☐	☐	
7.				
☐	☐	☐	☐	
8.				
9.				



699-18

+86 25 8556 6666

+86 25 8526 2330

ir@simcere.com

simcere.mediarelations@simcere.com